Glenmark Pharmaceuticals Limited (GLENMARK)
Outcome of Board Meeting
Half year ended 30/09/2026 results (unaudited):
Standalone:
Revenue 51.3bn +19.7% y-y (42.9bn)
EBITDA 15.3bn +16.7% y-y (13.1bn)
EBITDA margin 29.8% (30.5%) -70 bps y-y
PAT 2.5bn -17.1% y-y (3.0bn)
Consolidated:
Revenue 82.7bn +11.2% y-y (74.4bn)
EBITDA 20.8bn +10.6% y-y (18.8bn)
EBITDA margin 25.2% (25.3%) -10 bps y-y
PAT 4.8bn -7.5% y-y (5.2bn)
Dividend: None stated
Commentary: Exceptional items include a Rs 2.84bn charge related to a US subsidiary settlement and related legal and regulatory costs for the half year ended 30 September 2026.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLENMARK — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLENMARK to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Glenmark Pharmaceuticals Limited
Important.
The summary above is generated automatically from Glenmark Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.